Novo Holdings’ portfolio company ReViral Ltd (ReViral) is to be acquired by Pfizer for up to USD525 million in total deal value.
Founded in 2011, ReViral is a London, UK and Research Triangle Park, North Carolina based privately held clinical-stage biopharmaceutical company focused on discovering, developing, and commercialising novel antiviral therapeutics that target respiratory syncytial virus (RSV).
Novo Ventures, the venture capital team at Novo Holdings, led Novo Holdings’ first investment in ReViral in July 2018 co-leading a USD55 million Series B financing.
